Dual ProGlide versus ProGlide and FemoSeal for vascular access haemostasis after transcatheter aortic valve implantation

Gmeiner, Jonas M. D.; Linnemann, Marie; Steffen, Julius; Scherer, Clemens; Orban, Martin; Theiss, Hans; Mehilli, Julinda; Sadoni, Sebastian; Peterss, Sven; Joskowiak, Dominik; Hagl, Christian; Tsilimparis, Nikolaos; Curta, Adrian; Maurus, Stefan; Doldi, Philipp M.; Low, Kornelia; Haum, Magda; Roden, Daniel; Hausleiter, Jörg; Massberg, Steffen; Rizas, Konstantinos; Deseive, Simon und Braun, Daniel (2022): Dual ProGlide versus ProGlide and FemoSeal for vascular access haemostasis after transcatheter aortic valve implantation. In: Eurointervention, Bd. 18, Nr. 10: S. 812-819

Abstract

Background: Large-bore arteriotomy for transcatheter aortic valve implantation (TAVI) requires percuta-neous vascular closure devices, but real-world data comparing different closure strategies are limited. Aims: We sought to compare a dual ProGlide strategy vs a combination of one ProGlide and one FemoSeal for vascular closure after TAVI. Methods: We retrospectively analysed 874 propensity score-matched patients undergoing TAVI at the Munich University Hospital from August 2018 to October 2020. From August 2018 to August 2019, a dual ProGlide strategy was used for vascular closure. From October 2019 to October 2020, a combination of one ProGlide and one FemoSeal was used. The primary endpoint was defined as access-related major vascular complications or bleeding >= Type 2 according to Valve Academic Research Consortium 3 criteria. Results: Patients in the dual ProGlide group (n=437) had a higher incidence of the primary endpoint than patients treated with one ProGlide and one FemoSeal (n=437;11.4% vs 3.0%;p<0.001). Furthermore, they had a higher rate of closure device failure (2.7% vs 0.9%;p=0.044) and more often required unplanned sur-gery or endovascular treatment (3.9% vs 0.9%;p=0.004). The incidence of death did not differ significantly between groups (3.4% vs 1.6%;p=0.08). Conclusions: A combined ProGlide and FemoSeal strategy might have the potential to reduce access -related vascular complications following TAVI.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1774-024X
• Sprache: Englisch